Interestingly, canakinumab (a selective anti-IL-1β monoclonal antibody) decreased neutrophil counts to lower NLR, which in turn decreased adverse endpoint events of cardiovascular disease with no discernible effect from lipid levels, which may indicate that neutrophil played a more vital role (26). Here, IL1B is linked to cardiovascular disorder.